查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
歐洲非侵入性產前檢測 (NIPT) 市場：按方法、按平台、按最終用戶、按應用、按國家 - 分析和預測 (2023-2033)
市場調查報告書
商品編碼
1594218

歐洲非侵入性產前檢測 (NIPT) 市場：按方法、按平台、按最終用戶、按應用、按國家 - 分析和預測 (2023-2033)

Europe Non-Invasive Prenatal Testing (NIPT) Market: Focus on Method, Platform, End User, Application, and Country - Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 78 Pages | 商品交期: 1-5個工作天內

價格

2023年，歐洲非侵入性產前檢測（NIPT）市場規模達8.592億美元。預計到 2033 年，該市場將達到 32.306 億美元，2023-2033 年預測期間複合年成長率為 14.16%。歐洲 NIPT 市場的主要動力是有利指南的引入、將篩檢程序納入報銷政策、技術的持續進步、整個全部區域商業機會的擴大以及對非侵入性檢測方法的日益偏好。

主要市場統計數據
預測期 2023-2033
2023年評估 8.592 億美元
2033年預測 32.306 億美元
複合年成長率 14.16%

近年來，由於基因組技術的進步以及對更安全、更準確的產前篩檢技術的需求不斷成長，歐洲的非侵入性產前檢測（NIPT）市場顯著成長。這種突破性的方法被稱為 NIPT，透過分析母親血液中的胎兒遊離 DNA 來檢測染色體異常，例如帕陶氏症候群、愛德華茲症候群和唐氏症。由於 NIPT 是非侵入性的，因此它沒有羊膜穿刺術等傳統診斷技術的風險，因此受到準父母和醫療保健相關人員的青睞。

有利的法律規範、患者和醫療保健專業人員知識的增加以及 NIPT 納入公共和私人醫療保健系統都有助於市場成長。許多歐洲國家的報銷規定進一步推動了 NIPT 的普及，特別是在產前護理基礎設施完善的地區。

市場主要參與企業專注於提高 NIPT 服務的可負擔性、可近性和準確性的技術進步。此外，妊娠晚期和母親老化的趨勢增加了對可靠產前篩檢方法的需求。因此，歐洲 NIPT 市場預計將穩步擴大，有助於改善全部區域的孕產婦和胎兒醫療保健結果，並促進明智的決策。

該報告考察了歐洲無創產前檢測 (NIPT) 市場，提供了市場概況、方法、平台、最終用戶、應用、國家和進入市場的公司的概況等。

目錄

執行摘要

第1章 市場

  • 趨勢：當前和未來的影響評估
  • 供應鏈概覽
  • 研究發展回顧
  • 監管狀況
  • 贖回場景
  • 市場動態概覽

第2章 區域

  • 促進因素和抑制因素
  • 區域概況
  • 歐洲

第3章市場－競爭基準化分析與公司概況

  • 競爭格局
    • F. Hoffmann-La Roche Ltd
    • CENTOGENE NV
    • Yourgene Health
    • Eurofins Scientific SE

第4章調查方法

Product Code: BHL2393SS

Introduction to Europe Non-Invasive Prenatal Testing (NIPT) Market

The Europe NIPT market was valued at $859.2 million in 2023 and is expected to reach $3,230.6 million by 2033, registering a CAGR of 14.16% during the forecast period 2023-2033. The European NIPT market is primarily driven by the implementation of favorable guidelines, the inclusion of screening procedures in reimbursement policies, ongoing advancements in technology, expanding commercial opportunities across the region, and the growing preference for non-invasive testing methods.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$859.2 Million
2033 Forecast$3,230.6 Million
CAGR14.16%

The market for non-invasive prenatal testing (NIPT) in Europe has grown significantly in recent years due to the development of genomic technologies and the increased need for prenatal screening techniques that are safer and more accurate. The ground-breaking method known as NIPT looks for chromosomal abnormalities such Patau syndrome, Edwards syndrome, and Down syndrome by analyzing cell-free fetal DNA in the mother's bloodstream. It is a preferred choice for pregnant parents and medical professionals because of its non-invasive nature, which removes the hazards connected to conventional diagnostic techniques like amniocentesis.

Favorable regulatory frameworks, growing patient and healthcare professional knowledge, and the incorporation of NIPT into both public and private healthcare systems all contribute to the market's growth. Its popularity has been further accelerated by reimbursement regulations in a number of European nations, especially in areas with established prenatal care infrastructure.

The market's major players are concentrating on technology advancements to improve the NIPT services' affordability, accessibility, and accuracy. Furthermore, the necessity for trustworthy prenatal screening methods has increased due to the tendency of late pregnancies and the aging of mothers. Consequently, the NIPT market in Europe is expected to increase steadily, contributing to better maternal and fetal healthcare outcomes throughout the area and facilitating informed decision-making.

Market Segmentation:

Segmentation 1: by Application

  • Trisomy Detection
  • Microdeletion Detection
  • Sex Chromosome Aneuploidy Detection
  • Others

Segmentation 2: by End User

  • Hospitals
  • Diagnostic Laboratories
  • Others

Segmentation 3: by Platform

  • NGS
  • PCR
  • Others

Segmentation 4: by Method

  • cfDNA
  • FCMB

Segmentation 5: by Country

  • France
  • Germany
  • Italy
  • Spain
  • U.K.
  • Rest-of-Europe

How can this report add value to an organization?

Workflow/Innovation Strategy: The Europe NIPT market (by application) has been segmented into detailed segments of the application of NIPT based on applications, including trisomy detection, microdeletion detection, sex chromosome aneuploidy detection, and others.

Growth/Marketing Strategy: Constant advancement and innovation to enhance performance and efficiency can enabled prominent players to command premium prices while maintaining growth in revenue and volume.

Competitive Strategy: Key players in the Europe NIPT market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe NIPT market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Some prominent names established in this market are:

  • F. Hoffmann-La Roche Ltd
  • CENTOGENE N.V.
  • Yourgene Health
  • Eurofins Scientific SE

Table of Contents

Executive Summary

Scope and Definition

1 Markets

  • 1.1 Trends: Current and Future Impact Assessment
    • 1.1.1 Increasing Strategic Partnerships and Alliances between Market Players
    • 1.1.2 Expanding Applications in NIPT Products
  • 1.2 Supply Chain Overview
  • 1.3 Research and Development Review
    • 1.3.1 Patent Filing Trend (by Country, Year)
  • 1.4 Regulatory Landscape
    • 1.4.1 Regulatory Scenario in the U.K.
    • 1.4.2 Regulatory Scenario in Germany
    • 1.4.3 Regulatory Scenario in France
    • 1.4.4 Regulatory Scenario in Spain
    • 1.4.5 Regulatory Scenario in Italy
    • 1.4.6 Regulatory Scenario in the Netherlands
  • 1.5 Reimbursement Scenario
  • 1.6 Market Dynamics Overview
    • 1.6.1 Market Drivers
      • 1.6.1.1 High Incidence of Genetic Disorders
      • 1.6.1.2 Rising Maternal Age
      • 1.6.1.3 Increasing Number of Reimbursement Policies toward Genetic Coverage
      • 1.6.1.4 Increased Emphasis on Early Detection and Prevention
    • 1.6.2 Market Restraints
      • 1.6.2.1 Stringent Regulatory Guidelines and Ethical Hurdles
      • 1.6.2.2 Lack of Awareness Regarding NIPT
      • 1.6.2.3 Limitations and Considerations in Non-Invasive Prenatal Testing
    • 1.6.3 Market Opportunities
      • 1.6.3.1 Increasing Focus on Non-Invasive Pre-Implantation Genetic Testing (niPGT)

2 Regions

  • 2.1 Drivers and Restraints
  • 2.2 Regional Summary
  • 2.3 Europe
    • 2.3.1 Regional Overview
    • 2.3.2 Driving Factors for Market Growth
    • 2.3.3 Factors Challenging the Market
    • 2.3.4 Application
    • 2.3.5 Product
    • 2.3.6 France
    • 2.3.7 Germany
    • 2.3.8 U.K.
    • 2.3.9 Spain
    • 2.3.10 Italy
    • 2.3.11 Rest-of-Europe

3 Markets - Competitive Benchmarking & Company Profiles

  • 3.1 Competitive Landscape
    • 3.1.1 F. Hoffmann-La Roche Ltd
      • 3.1.1.1 Overview
      • 3.1.1.2 Product Portfolio
      • 3.1.1.3 Top Competitors
      • 3.1.1.4 Target Customers
      • 3.1.1.5 Key Personnel
      • 3.1.1.6 Analyst View
    • 3.1.2 CENTOGENE N.V.
      • 3.1.2.1 Overview
      • 3.1.2.2 Product Portfolio
      • 3.1.2.3 Top Competitors
      • 3.1.2.4 Target Customers
      • 3.1.2.5 Key Personnel
      • 3.1.2.6 Analyst View
    • 3.1.3 Yourgene Health
      • 3.1.3.1 Overview
      • 3.1.3.2 Product Portfolio
      • 3.1.3.3 Top Competitors
      • 3.1.3.4 Target Customers
      • 3.1.3.5 Key Personnel
      • 3.1.3.6 Analyst View
    • 3.1.4 Eurofins Scientific SE
      • 3.1.4.1 Overview
      • 3.1.4.2 Product Portfolio
      • 3.1.4.3 Top Competitors
      • 3.1.4.4 Target Customers
      • 3.1.4.5 Key Personnel
      • 3.1.4.6 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Non-Invasive Prenatal Testing Market (by Region), $Million, 2022, 2026, and 2033
  • Figure 2: Europe Non-Invasive Prenatal Testing Market (by Application), $Million, 2022, 2026, and 2033
  • Figure 3: Europe Non-Invasive Prenatal Testing Market (by End User), $Million, 2022, 2026, and 2033
  • Figure 4: Europe Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022, 2026, and 2033
  • Figure 5: Europe Non-Invasive Prenatal Testing Market (by Method), $Million, 2022, 2026, and 2033
  • Figure 6: Non-Invasive Prenatal Testing Market, Recent Developments, 2023
  • Figure 7: Supply Chain of NIPT Market
  • Figure 8: NIPT Market, Patent Analysis, (by Country), January 2020-December 2023
  • Figure 9: NIPT Market, Patent Analysis, (by Year), January 2020-December 2023
  • Figure 10: Reimbursement Scenario in Major Countries of the Europe NIPT Market
  • Figure 11: Impact Analysis of Market Navigating Factors, 2022-2033
  • Figure 12: Births with Trisomies per 100,000 Live Births in Europe Region, 2000-2021
  • Figure 13: Age of Mother at Childbirth over the Years
  • Figure 14: Reimbursement Scenario in Major Countries
  • Figure 15: Number of Tests Processed by Natera, Inc., 2018-2020
  • Figure 16: Positives from Data of 75,000 NIPT Tests Showing False Positives
  • Figure 17: Europe Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 18: Europe Non-Invasive Prenatal Testing Market, $Million, 2023-2033
  • Figure 19: France Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 20: France Non-Invasive Prenatal Testing Market, $Million, 2023-2033
  • Figure 21: Germany Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 22: Germany Non-Invasive Prenatal Testing Market, $Million, 2023-2033
  • Figure 23: U.K. Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 24: U.K. Non-Invasive Prenatal Testing Market, $Million, 2022-2033
  • Figure 25: Spain Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 26: Spain Non-Invasive Prenatal Testing Market, $Million, 2022-2033
  • Figure 27: Italy Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 28: Italy Non-Invasive Prenatal Testing Market, $Million, 2022-2033
  • Figure 29: Rest-of-Europe Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 30: Rest-of-Europe Non-Invasive Prenatal Testing Market, $Million, 2022-2033
  • Figure 31: Share of Strategic Initiatives
  • Figure 32: Data Triangulation
  • Figure 33: Top-Down and Bottom-Up
  • Figure 34: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Non-Invasive Prenatal Testing Market, Opportunities
  • Table 3: Key Companies' Partnerships and Alliances
  • Table 4: NIPT Tests in the NIPT Market and their Corresponding Applications
  • Table 5: Risk of Chromosomal Abnormality w.r.t Maternal Age
  • Table 6: Non-Invasive Prenatal Testing Market (by Region), Thousands Units, 2022-2033
  • Table 7: Non-Invasive Prenatal Testing Market (by Region), $Million, 2022-2033
  • Table 8: Europe Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 9: Europe Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 10: Europe Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 11: Europe Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 12: France Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 13: France Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 14: France Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 15: France Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 16: Germany Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 17: Germany Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 18: Germany Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 19: Germany Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 20: U.K. Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 21: U.K. Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 22: U.K. Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 23: U.K. Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 24: Spain Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 25: Spain Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 26: Spain Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 27: Spain Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 28: Italy Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 29: Italy Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 30: Italy Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 31: Italy Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 32: Rest-of-Europe Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 33: Rest-of-Europe Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 34: Rest-of-Europe Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 35: Rest-of-Europe Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 36: Market Share (2022)